Regeneron Pharmaceuticals, Inc.

Regeneran Pharmaceuticals, Inc.

Other

Duke University

Lynn Macdonald

Andrew J Murphy

Sean Stevens

Cagan Gurer

John R McWhirter

Naxin Tu

Karolina Meagher

Vera Voronina

Margaret Karow

David M Valenzuela

George D Yancopoulos

Aris N Economides

Marc R Morra

Joel H Martin

Michael L LaCroix-Fralish

Faith Harris

Richard Torres

Joel C Reinhardt

Karolina A Hosiawa

Ka-Man Venus Lai

Susan D Croll

Jose F Rojas

Min Gao

Nicholas J Papadopoulos

Yajun Tang

Yingzi Xue

David Frendewey

Ying Hu

Alexander O Mujica

Gustavo Droguett

Aris I Baras

Wojtek Auerbach

Israel Lowy

Robert Babb

Li-Hsien Wang

Brian Zambrowicz

Lori C Morton

Jeffrey D Lee

Carmelo Romano

Samuel H Davis

Neil E Stahl

Christos Kyratsous

Tammy T Huang

Stanley J Wiegand

Ashique Rafique

Jingtai Cao

Chia-Jen Siao

David Heslin

Nicole M Alessandri-Haber

Chunguang Guo

Paul Tiseo

Corey Momont

Gregg S Warshaw

Chris Schoenherr

Natasha Levenkova

Robert R Salzler

Caitlin Montagna

Anthony Gagliardi

Dan Chalothorn

Garnett Kelsoe

Brinda Prasad

David R Buckler

Lyndon Mitnaul

John Mcwhirter

Barton F Haynes

Daria Zamolodchikov

John McWhirter

Caitlin L Goshert

Nicole M Alessandri Haber

Marine Prissette

Adrianna Latuszek

Ergang Shi

Daisuke Kajimura

Aarti Sharma-Kanning

Hsin Chieh Lin

Aristides Economides

Ashok Badithe

Roxanne Ally

Karolina A Meagher

Michael L Lacroix-Fralish

Alexander Mujica

Stanley Wiegand

Michael Lacroix-Fralish

John Mcwhirther

Andrew Murphy

Yi Wei

The present disclosure provides antibodies and antigen-binding fragments thereof that bind to human artemin. Methods for using anti-artemin antibodies and antigen-binding fragments are also provided.

Human antibodies to artemin and methods of use thereof

Non-human animals, tissues, cells, and genetic material are provided that comprise a modification of an endogenous non-human heavy chain immunoglobulin sequence and that comprise an ADAM6 activity functional in a mouse, wherein the non-human animals express a human immunoglobulin heavy chain variable domain and a cognate human immunoglobulin λ light chain variable domain.

Humanized light chain mice

Non-human animals, cells, methods and compositions for making and using the same are provided, wherein the non-human animals and cells comprise a humanized a proliferation-inducing ligand gene. Non-human animals and cells that express a human or humanized a proliferation-inducing ligand protein from an endogenous a proliferation-inducing ligand locus are described.

Non-human animals having a humanized a proliferation-inducing ligand gene

Non-human animals (and/or non-human cells) and methods of using and making the same are provided, which non-human animals (and/or non-human cells) have a genome comprising human antibody-encoding sequences (i.e., immunoglobulin genes). Non-human animals described herein express antibodies that contain human Igλ light chains, in whole or in part. In particular, non-human animals provided herein are, in some embodiments, characterized by expression of antibodies that contain human Igλ light chains, in whole or in part, that are encoded by human Igλ light chain-encoding sequences inserted into an endogenous Igλ light chain locus of said non-human animals. Methods for producing antibodies from non-human animals are also provided.

Non-human animals having an engineered immunoglobulin lambda light chain locus

The invention provides genetically modified non-human animals that express chimeric human/non-human MHC I and MHC II polypeptides and/or human or humanized β2 microglobulin polypeptide, as well as embryos, cells, and tissues comprising the same. Also provided are constructs for making said genetically modified animals and methods of making the same. Methods of using the genetically modified animals to study various aspects of human immune system are provided.

Genetically modified major histocompatibility complex mice

Non-human animal genomes, non-human animal cells, and non-human animals comprising a humanized TRKB locus and methods of making and using such non-human animal genomes, non-human animal cells, and non-human animals are provided. Non-human animal cells or non-human animals comprising a humanized TRKB locus express a human TRKB protein or a chimeric transthyretin protein, fragments of which are from human TRKB. Methods are provided for using such non-human animals comprising a humanized TRKB locus to assess in vivo efficacy of human-TRKB-targeting reagents such as nuclease agents designed to target human TRKB.

Mouse comprising a humanized TRKB locus

A genetically modified mouse is provided, wherein the mouse expresses an immunoglobulin light chain repertoire characterized by a limited number of light chain variable domains. Mice are provided that present a choice of two human light chain variable gene segments such that the immunoglobulin light chains expresses by the mouse comprise one of the two human light chain variable gene segments. Methods for making bispecific antibodies having universal light chains using mice as described herein, including human light chain variable regions, are provided. Methods for making human variable regions suitable for use in multispecific binding proteins, e.g., bispecific antibodies, and host cells are provided.

Mice expressing a limited immunoglobulin light chain repertoire

Non-human animals (and/or non-human cells) and methods of using the same are provided, which non-human animals (and/or non-human cells) have a genome comprising human antibody-encoding sequences (i.e., immunoglobulin genes). Non-human animals described herein express antibodies that contain immunoglobulin (Ig) light chains characterized by the presence of human Vλ domains. Non-human animals provided herein are, in some embodiments, characterized by expression of antibodies that contain human Vλ light chains that are encoded by human Igλ light chain-encoding sequences inserted into an endogenous Igκ light chain locus of said non-human animals. Methods for producing antibodies from non-human animals are also provided, which antibodies contain human variable regions and mouse constant regions.

Immunoglobulin lambda light chain and uses thereof

Methods and compositions are provided for generating antigen-binding proteins against a foreign antigen of interest.

Methods for producing antigen-binding proteins against foreign antigens

Provided herein are methods and compositions related to non-human animals that express exogenous Terminal Deoxynucleotidyltransferase (TdT).

Non-human animals expressing exogenous terminal deoxynucleotidyltransferase

Mice are provided that comprise a reduction or deletion of ADAM6 activity from an endogenous ADAM6 locus, or that lack an endogenous locus encoding a mouse ADAM6 protein, wherein the mice comprise a sequence encoding an ADAM6 or ortholog or homolog or fragment thereof that is functional in a male mouse. In one embodiment, the sequence is an ectopic ADAM6 sequence or a sequence that confers upon a male mouse the ability to generate offspring by mating. Mice and cells with genetically modified immunoglobulin heavy chain loci that comprise an ectopic nucleotide sequence encoding a mouse ADAM6 or functional fragment or homolog or ortholog thereof are also provided.

ADAM6 mice

Non-human animal genomes, non-human animal cells, and non-human animals comprising a humanized coagulation factor XII (F12) locus and methods of making and using such non-human animal genomes, non-human animal cells, and non-human animals are provided. Non-human animal cells or non-human animals comprising a humanized F12 locus express a human coagulation factor XII protein or a chimeric coagulation factor XII protein, fragments of which are from human coagulation factor XII. Methods are provided for using such non-human animals comprising a humanized F12 locus to assess in vivo efficacy of human-coagulation-factor-XII-targeting reagents such as nuclease agents designed to target human F12. A short isoform of F12 that is produced locally in the brain, and methods of using the short isoform, are also provide.

Non-human animals comprising a humanized coagulation factor 12 locus

Disclosed herein are genetically modified rodent animals comprising in their genome a nucleic acid which comprises a nucleotide sequence encoding a human CR1 polypeptide, wherein the rodent animals display a human-like expression of the human CR1 polypeptide. Also disclosed herein are isolated rodent cells including rodent embryonic stem cells, and rodent tissues. Further disclosed are nucleic acid vectors and methods for making the genetically modified rodent animals, as well as methods of using such genetically modified rodent animals for screening and testing candidate compounds.

Rodent animals expressing human CR1

The invention provides genetically modified non-human animals that express chimeric human/non-human T cell co-receptor polypeptides (e.g., CD4, CD8α, CD8β), as well as embryos, cells, and tissues comprising the same. Also provided are constructs for making said genetically modified animals and methods of making the same.

Humanized T cell co-receptor mice

Non-human animals, cells, methods and compositions for making and using the same are provided, wherein the non-human animals and cells comprise a humanized B-cell activating factor gene. Non-human animals and cells that express a human or humanized B-cell activating factor protein from an endogenous B-cell activating factor locus are described.

Mouse having a humanized B-cell activating factor gene

Growing community of inventors

Harrison, NY, United States of America

Lynn Macdonald